Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer (CILAB)

April 6, 2016 updated by: Sanofi

Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

This is a randomized, open-label, multi-center study comparing the efficacy and safety of XRP9881 plus cisplatin to gemcitabine plus cisplatin in the first line treatment of locally advanced/metastatic urothelial tract or bladder cancer. The primary objective is to compare overall survival. Secondary objectives include comparisons of progression free survival, objective response rate, time to definitive deterioration of performance status, duration of response, time to definitive weight loss, and assessments of overall safety, and pharmacokinetics. Patients are treated until disease progression, death, or unacceptable toxicity and are followed-up until death or the end of the study whichever comes first.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
337

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1120AAT
        • Sanofi-Aventis Investigational Site Number 032002
      • Ciudad De Buenos Aires, Argentina, C1426BOR
        • Sanofi-Aventis Investigational Site Number 032003
      • Mendoza, Argentina, 5500
        • Sanofi-Aventis Investigational Site Number 032004
      • Rosario, Argentina, 2000
        • Sanofi-Aventis Investigational Site Number 032005
      • Santa Fe, Argentina, 3000
        • Sanofi-Aventis Investigational Site Number 032001
  • Australia
      • Adelaide, Australia, 5000
        • Sanofi-Aventis Investigational Site Number 036002
      • Bedford Park, Australia, 5042
        • Sanofi-Aventis Investigational Site Number 036003
      • St Leonards, Australia, 2065
        • Sanofi-Aventis Investigational Site Number 036004
  • Belgium
      • Aalst, Belgium, 9300
        • Sanofi-Aventis Investigational Site Number 056005
      • Bruxelles, Belgium, 1000
        • Sanofi-Aventis Investigational Site Number 056001
      • Bruxelles, Belgium, 1200
        • Sanofi-Aventis Investigational Site Number 056002
      • Ottignies, Belgium, 1340
        • Sanofi-Aventis Investigational Site Number 056004
      • Wilrijk, Belgium, 2610
        • Sanofi-Aventis Investigational Site Number 056003
      • Yvoir, Belgium, 5530
        • Sanofi-Aventis Investigational Site Number 056006
  • Brazil
      • Barretos, Brazil, 14784-400
        • Sanofi-Aventis Investigational Site Number 076006
      • Florianopolis, Brazil, 88034-000
        • Sanofi-Aventis Investigational Site Number 076004
      • Porto Alegre, Brazil, 90110-270
        • Sanofi-Aventis Investigational Site Number 076001
      • Porto Alegre, Brazil, 90610-000
        • Sanofi-Aventis Investigational Site Number 076003
      • Rio De Janeiro, Brazil, 20231-050
        • Sanofi-Aventis Investigational Site Number 076002
      • Sao Paulo, Brazil, 01246-000
        • Sanofi-Aventis Investigational Site Number 076007
      • Sao Paulo, Brazil, 04122 000
        • Sanofi-Aventis Investigational Site Number 076005
  • Canada
      • Edmonton, Canada, T6G1Z2
        • Sanofi-Aventis Investigational Site Number 124007
      • London, Canada, N6A 4L6
        • Sanofi-Aventis Investigational Site Number 124001
      • Montreal, Canada, H2L 4M1
        • Sanofi-Aventis Investigational Site Number 124006
      • Quebec, Canada, G1R 2J6
        • Sanofi-Aventis Investigational Site Number 124003
      • Weston, Canada, M9N 1N8
        • Sanofi-Aventis Investigational Site Number 124002
  • Chile
      • Santiago, Chile, 8380455
        • Sanofi-Aventis Investigational Site Number 152001
  • France
      • Avignon, France, 84082
        • Sanofi-Aventis Investigational Site Number 250006
      • Bordeaux Cedex, France, 33076
        • Sanofi-Aventis Investigational Site Number 250003
      • Hyeres, France, 83400
        • Sanofi-Aventis Investigational Site Number 250005
      • Le Mans, France, 72015
        • Sanofi-Aventis Investigational Site Number 250011
      • Lyon, France, 69008
        • Sanofi-Aventis Investigational Site Number 250004
      • Perpignan, France, 66012
        • Sanofi-Aventis Investigational Site Number 250012
      • Poitiers Cedex, France, 86021
        • Sanofi-Aventis Investigational Site Number 250007
      • Saint Herblain, France, 44805
        • Sanofi-Aventis Investigational Site Number 250008
      • Strasbourg, France, 67091
        • Sanofi-Aventis Investigational Site Number 250009
      • Suresnes, France, 92151
        • Sanofi-Aventis Investigational Site Number 250001
  • India
      • Bangalore, India, 560029
        • Sanofi-Aventis Investigational Site Number 356003
      • Kolkata, India, 700026
        • Sanofi-Aventis Investigational Site Number 356007
      • New Delhi, India, 110 029
        • Sanofi-Aventis Investigational Site Number 356004
      • New Delhi, India, 110001
        • Sanofi-Aventis Investigational Site Number 356001
      • Vellore, India, 632004
        • Sanofi-Aventis Investigational Site Number 356002
      • Vishakhapatnam, India, 530002
        • Sanofi-Aventis Investigational Site Number 356005
  • Israel
      • Haifa, Israel, 31096
        • Sanofi-Aventis Investigational Site Number 376005
      • Kfar Saba, Israel, 44281
        • Sanofi-Aventis Investigational Site Number 376004
      • Petah-Tikva, Israel, 49100
        • Sanofi-Aventis Investigational Site Number 376003
      • Tel Aviv, Israel, 64239
        • Sanofi-Aventis Investigational Site Number 376002
      • Tel Hashomer, Israel, 52621
        • Sanofi-Aventis Investigational Site Number 376007
      • Tzrifin, Israel, 70300
        • Sanofi-Aventis Investigational Site Number 376001
  • Italy
      • Bari, Italy, 70124
        • Sanofi-Aventis Investigational Site Number 380004
      • Lecce, Italy, 73100
        • Sanofi-Aventis Investigational Site Number 380003
      • Meldola, Italy, 47014
        • Sanofi-Aventis Investigational Site Number 380005
      • Pavia, Italy, 27100
        • Sanofi-Aventis Investigational Site Number 380006
      • Perugia, Italy, 06128
        • Sanofi-Aventis Investigational Site Number 380002
      • Roma, Italy, 00152
        • Sanofi-Aventis Investigational Site Number 380001
      • Viterbo, Italy, 01100
        • Sanofi-Aventis Investigational Site Number 380008
  • Mexico
      • Aguascalientes, Mexico, 20230
        • Sanofi-Aventis Investigational Site Number 484003
      • Chihuahua, Mexico, 31000
        • Sanofi-Aventis Investigational Site Number 484007
      • Chihuahua, Mexico, 31205
        • Sanofi-Aventis Investigational Site Number 484005
      • Monterrey, Mexico, 64988
        • Sanofi-Aventis Investigational Site Number 484004
  • Netherlands
      • Amsterdam, Netherlands, 1091 HA
        • Sanofi-Aventis Investigational Site Number 528005
      • Arnhem, Netherlands, 6815 AD
        • Sanofi-Aventis Investigational Site Number 528002
      • Hoofddorp, Netherlands, 2134 TM
        • Sanofi-Aventis Investigational Site Number 528006
      • Maastricht, Netherlands, 6229 HX
        • Sanofi-Aventis Investigational Site Number 528003
      • Nijmegen, Netherlands, 6525 GA
        • Sanofi-Aventis Investigational Site Number 528004
      • Sittard-Geleen, Netherlands, 6162 BG
        • Sanofi-Aventis Investigational Site Number 528001
      • Zwolle, Netherlands, 8025 AB
        • Sanofi-Aventis Investigational Site Number 528007
  • Poland
      • Poznan, Poland, 61-485
        • Sanofi-Aventis Investigational Site Number 616002
      • Rybnik, Poland, 44-200
        • Sanofi-Aventis Investigational Site Number 616004
      • Warszawa, Poland, 02-781
        • Sanofi-Aventis Investigational Site Number 616001
      • Wroclaw, Poland, 51-124
        • Sanofi-Aventis Investigational Site Number 616005
  • Russian Federation
      • Chelyabinsk, Russian Federation, 454087
        • Sanofi-Aventis Investigational Site Number 643009
      • Kursk, Russian Federation, 305035
        • Sanofi-Aventis Investigational Site Number 643010
      • Moscow, Russian Federation, 105425
        • Sanofi-Aventis Investigational Site Number 643006
      • Moscow, Russian Federation, 115478
        • Sanofi-Aventis Investigational Site Number 643008
      • Moscow, Russian Federation, 117837
        • Sanofi-Aventis Investigational Site Number 643004
      • Moscow, Russian Federation, 125284
        • Sanofi-Aventis Investigational Site Number 643005
      • Obninsk, Russian Federation, 249036
        • Sanofi-Aventis Investigational Site Number 643001
      • Saint-Petersburg, Russian Federation, 194354
        • Sanofi-Aventis Investigational Site Number 643003
      • Saint-Petersburg, Russian Federation, 197758
        • Sanofi-Aventis Investigational Site Number 643007
      • St-Petersburg, Russian Federation, 191104
        • Sanofi-Aventis Investigational Site Number 643002
      • St-Petersburg, Russian Federation, 197758
        • Sanofi-Aventis Investigational Site Number 643011
  • South Africa
      • Bloemfontein, South Africa, 9301
        • Sanofi-Aventis Investigational Site Number 710008
      • Cape Town, South Africa, 7506
        • Sanofi-Aventis Investigational Site Number 710003
      • Cape Town, South Africa, 7956
        • Sanofi-Aventis Investigational Site Number 710001
      • Durban, South Africa, 4062
        • Sanofi-Aventis Investigational Site Number 710007
      • Durban, South Africa, 4091
        • Sanofi-Aventis Investigational Site Number 710009
      • Port Elizabeth, South Africa, 6001
        • Sanofi-Aventis Investigational Site Number 710006
      • Pretoria, South Africa, 0181
        • Sanofi-Aventis Investigational Site Number 710005
  • Spain
      • Badalona, Spain, 08916
        • Sanofi-Aventis Investigational Site Number 724006
      • Barcelona, Spain, 08036
        • Sanofi-Aventis Investigational Site Number 724002
      • Barcelona, Spain, 08003
        • Sanofi-Aventis Investigational Site Number 724001
      • Barcelona, Spain, 08025
        • Sanofi-Aventis Investigational Site Number 724004
      • Barcelona, Spain, 08035
        • Sanofi-Aventis Investigational Site Number 724008
      • Madrid, Spain, 28041
        • Sanofi-Aventis Investigational Site Number 724003
      • Oviedo, Spain, 33006
        • Sanofi-Aventis Investigational Site Number 724010
      • Palma De Mallorca, Spain, 07014
        • Sanofi-Aventis Investigational Site Number 724013
      • Palma De Mallorca, Spain, 07198
        • Sanofi-Aventis Investigational Site Number 724007
      • Pamplona, Spain, 31008
        • Sanofi-Aventis Investigational Site Number 724009
      • Santiago De Compostela, Spain, 15706
        • Sanofi-Aventis Investigational Site Number 724011
      • Zaragoza, Spain, 50009
        • Sanofi-Aventis Investigational Site Number 724012
  • Sweden
      • Umeå, Sweden, 901 85
        • Sanofi-Aventis Investigational Site Number 752001
      • Uppsala, Sweden, 751 85
        • Sanofi-Aventis Investigational Site Number 752002
  • Turkey
      • Ankara, Turkey, 06100
        • Sanofi-Aventis Investigational Site Number 792002
      • Ankara, Turkey, 065090
        • Sanofi-Aventis Investigational Site Number 792003
      • Ankara, Turkey, 61080
        • Sanofi-Aventis Investigational Site Number 792004
      • Istanbul, Turkey, 22030
        • Sanofi-Aventis Investigational Site Number 792006
      • Istanbul, Turkey, 34093
        • Sanofi-Aventis Investigational Site Number 792001
  • United States
    • Alaska
      • Anchorage, Alaska, United States, 99508
        • Sanofi-Aventis Investigational Site Number 840068
    • California
      • Berkeley, California, United States, 94704
        • Sanofi-Aventis Investigational Site Number 840035
      • Burbank, California, United States, 91505
        • Sanofi-Aventis Investigational Site Number 840012
      • La Jolla, California, United States, 92037
        • Sanofi-Aventis Investigational Site Number 840029
      • Los Angeles, California, United States, 90033
        • Sanofi-Aventis Investigational Site Number 840046
      • Sacramento, California, United States, 95817
        • Sanofi-Aventis Investigational Site Number 840003
      • San Bernardino, California, United States, 92404
        • Sanofi-Aventis Investigational Site Number 840005
      • San Diego, California, United States, 92103
        • Sanofi-Aventis Investigational Site Number 840033
    • Colorado
      • Denver, Colorado, United States, 80262
        • Sanofi-Aventis Investigational Site Number 840031
    • Connecticut
      • Stamford, Connecticut, United States, 06902
        • Sanofi-Aventis Investigational Site Number 840032
    • District of Columbia
      • Washington, District of Columbia, United States, 20007
        • Sanofi-Aventis Investigational Site Number 840034
      • Washington, District of Columbia, United States, 20010
        • Sanofi-Aventis Investigational Site Number 840021
    • Florida
      • Boca Raton, Florida, United States, 33486
        • Sanofi-Aventis Investigational Site Number 840001
      • Boynton Beach, Florida, United States, 33435
        • Sanofi-Aventis Investigational Site Number 840048
      • Jacksonville, Florida, United States, 32224
        • Sanofi-Aventis Investigational Site Number 840049
      • Lakeland, Florida, United States, 33805
        • Sanofi-Aventis Investigational Site Number 840061
    • Georgia
      • Athens, Georgia, United States, 30607
        • Sanofi-Aventis Investigational Site Number 840060
    • Idaho
      • Boise, Idaho, United States, 83712
        • Sanofi-Aventis Investigational Site Number 840030
    • Illinois
      • Maywood, Illinois, United States, 60153
        • Sanofi-Aventis Investigational Site Number 840024
      • Peoria, Illinois, United States, 61615
        • Sanofi-Aventis Investigational Site Number 840062
    • Indiana
      • Goshen, Indiana, United States, 46526
        • Sanofi-Aventis Investigational Site Number 840039
    • Kansas
      • Kansas City, Kansas, United States, 66160-7321
        • Sanofi-Aventis Investigational Site Number 840054
    • Kentucky
      • Paducah, Kentucky, United States, 42002
        • Sanofi-Aventis Investigational Site Number 840057
    • Louisiana
      • Metarie, Louisiana, United States, 70006-290
        • Sanofi-Aventis Investigational Site Number 840004
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • Sanofi-Aventis Investigational Site Number 840045
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Sanofi-Aventis Investigational Site Number 840006
      • Lansing, Michigan, United States, 48510
        • Sanofi-Aventis Investigational Site Number 840026
      • St. Joseph, Michigan, United States, 49805
        • Sanofi-Aventis Investigational Site Number 840047
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
        • Sanofi-Aventis Investigational Site Number 840009
    • New York
      • Lake Success, New York, United States, 11042
        • Sanofi-Aventis Investigational Site Number 840044
      • New York, New York, United States, 10021
        • Sanofi-Aventis Investigational Site Number 840013
      • New York, New York, United States, 10032
        • Sanofi-Aventis Investigational Site Number 840050
      • Rochester, New York, United States, 14642
        • Sanofi-Aventis Investigational Site Number 840056
      • Syracuse, New York, United States, 13210
        • Sanofi-Aventis Investigational Site Number 840015
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • Sanofi-Aventis Investigational Site Number 840041
      • Charlotte, North Carolina, United States, 28204
        • Sanofi-Aventis Investigational Site Number 840007
    • Ohio
      • Sylvania, Ohio, United States, 43560
        • Sanofi-Aventis Investigational Site Number 840019
    • Pennsylvania
      • Bethlehem, Pennsylvania, United States, 18015
        • Sanofi-Aventis Investigational Site Number 840020
      • Dunmore, Pennsylvania, United States, 18512
        • Sanofi-Aventis Investigational Site Number 840065
    • Rhode Island
      • Woonsocket, Rhode Island, United States, 02895
        • Sanofi-Aventis Investigational Site Number 840058
    • South Carolina
      • Charleston, South Carolina, United States, 29406
        • Sanofi-Aventis Investigational Site Number 840052
    • Tennessee
      • Knoxville, Tennessee, United States, 37920
        • Sanofi-Aventis Investigational Site Number 840002
    • Texas
      • Houston, Texas, United States, 77014
        • Sanofi-Aventis Investigational Site Number 840008
      • Houston, Texas, United States, 77030
        • Sanofi-Aventis Investigational Site Number 840018
      • Lubbock, Texas, United States, 79415
        • Sanofi-Aventis Investigational Site Number 840017
      • San Antonio, Texas, United States, 78229
        • Sanofi-Aventis Investigational Site Number 840016
      • Temple, Texas, United States, 76508
        • Sanofi-Aventis Investigational Site Number 840064
      • Woodlands, Texas, United States, 77380
        • Sanofi-Aventis Investigational Site Number 840010
    • Washington
      • Seattle, Washington, United States, 98111
        • Sanofi-Aventis Investigational Site Number 840036
    • Wisconsin
      • Madison, Wisconsin, United States, 53792
        • Sanofi-Aventis Investigational Site Number 840011
      • Marshfield, Wisconsin, United States, 54449
        • Sanofi-Aventis Investigational Site Number 840025
      • Milwaukee, Wisconsin, United States, 53226
        • Sanofi-Aventis Investigational Site Number 840038

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with histology/cytology confirmed Transitional Cell Carcinoma (TCC) with locally advanced (T4b) or metastatic urothelial tract or bladder cancer
  • ECOG Performance Status 0 or 1
  • No prior palliative chemotherapy

Exclusion Criteria:

  • (Neo)Adjuvant chemotherapy if < 6 months between end of (neo)adjuvant chemotherapy and relapse
  • Less than 6 weeks elapsed from prior radiotherapy and less than 3 weeks from surgery to time of randomization
  • Prior cisplatin as (neo)adjuvant chemotherapy with cumulative dose > 300 mg/m²

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: 1
Drug: larotaxel (XRP9881)
administered on day 1 as a 1-hour infusion
Drug: cisplatin
1 hour infusion administered on day 1, 30 minutes after the other treatment
Active Comparator: 2
Drug: cisplatin
1 hour infusion administered on day 1, 30 minutes after the other treatment
Drug: gemcitabine
administered on day 1, 8 and 15 as a 30-minute infusion

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Overall survival defined as the time interval from the date of randomization to the date of death due to any cause
Time Frame: study period
study period

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Radiological tumor assessments (CT/MRI)
Time Frame: at screening, every 8 weeks during treatment, at end of treatment, and in follow-up until documented disease progression
at screening, every 8 weeks during treatment, at end of treatment, and in follow-up until documented disease progression
Adverse Events, laboratory assessments, vital signs, Physical Examinations, and ECOG Performance Status
Time Frame: at screening and every cycle
at screening and every cycle

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Sanofi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 1, 2008

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 1, 2011

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2011

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 19, 2008

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 19, 2008

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 28, 2008

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 5, 2016

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 6, 2016

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • EFC6668
  • EUDRACT: 2007-001943-23

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings